We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Xianglin Du

Xianglin L Du MB, MS, PhD

Professor of Epidemiology, Division of Epidemiology, Human Genetics, and Environmental Sciences, The University of Texas School of Public Health, Houston, Texas

Dr. Du completed his medical degree and his MS in clinical epidemiology at the Anhui Medical University in China, and his PhD in epidemiology and public health at the University of Manchester, England. He has extensive experience and skills in studies for cancer epidemiology research in China, England and the United States. Much of his research is focused on cancer health service and outcomes, health disparities, clinical comparative effectiveness and post-marketing surveillance of adverse-events of cancer therapies using SEER cancer registry data and SEER-Medicare linked data in large cohorts of patients with common types of cancer, including breast, lung, colorectal, prostate, cervical, ovarian, head and neck, and hepatocellular cancer, melanoma, lymphoma, and multiple myeloma. Dr. Du is currently the PI of an AHRQ funded R01 project (grant # R01HS018956-01A1) that aims to examine the comparative effectiveness and cost effectiveness of cancer chemotherapy in patients aged 65 and older with breast, ovarian, lung and colorectal cancer, and also the PI of a grant entitled “Impact of Health Insurance on Racial Disparities in Cancer Screening, Diagnosis, Treatment and Survival in Texas” funded by the Cancer Prevention and Research Institute of Texas (CPRIT, grant # RP130051). He was co-investigator/mentor for two training grants funded by the Susan J. Komen for the Cure Foundation. He is an advisory board member and mentor for the R25 training grant on cancer prevention at the UTSPH. He additionally serves as mentor for two NIH T32 training grants at UT-MD Anderson Cancer Center and Baylor College of Medicine in Houston. Dr. Du has published 120 articles (117 original and 3 review articles) in peer-reviewed professional journals.

Dr. Du has been actively involved in teaching, advising and mentoring graduate students or postdoctoral fellows in the UTSPH. His teaching excellence has been recognized by both faculty and students. Dr. Du was selected by the students of the UTSPH for the prestigious ‘John P. McGovern Outstanding Teacher’ award in 2008. He also received two Dean’s teaching excellence awards in 2009 and 2010. Moreover, he has offered numerous individual studies to students on cancer health service/outcomes and health disparities research. He has been directly involved in advising 65 graduate students (and he served as advisor for 41 of them) between 2004 and 2013, of whom 51 have graduated (including 18 PhDs and 2 DrPHs). He also mentored 3 post-doctoral fellows, 5 clinical fellows and 4 junior faculty investigators who have now gone on to successfully become independent scientists. Furthermore, Dr. Du has advised or mentored his trainees to be the first author for 54 articles published in peer-reviewed scientific journals.